This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The conventional strategy consisted of a clinical history, a physical examination, and clinical tests by echocardiography and electrocardiogram. The genetic strategy included a clinical history, which was followed by screening of the four genes most commonly associated with hypertrophic cardiomyopathy, which were MYH7, MYBPC3, TNNT2, and TNNI3.
These two screening strategies were analysed as one-off screening or with repeated screening every five years for those who tested negative.
Each strategy assessed the risk of sudden cardiac death, due to hypertrophic cardiomyopathy, for the first-degree asymptomatic cascading family members (children aged between 18 and 22 years) of a patient diagnosed with hypertrophic cardiomyopathy.
Location/setting
UK/secondary care.
Methods

Analytical approach:
The economic evaluation was based on a decision-tree model with a lifetime horizon. The authors stated that the analysis was carried out from the perspective of the hospital.
Effectiveness data:
The clinical inputs were derived from a literature review, in medical and economic databases. Expert opinions were used when published data were not available. For example, no published randomised controlled trials were found that assessed the effectiveness of the treatment in preventing sudden cardiac death and this was therefore based on expert opinion. The accuracy of the screening tests (both clinical and genetic) was the key model input and it was from published studies and expert opinions.
Monetary benefit and utility valuations:
Not considered.
